CD4 News and Research

RSS

Scientists provide first-ever glimpse of HIV protein structure

Scientists from the California Institute of Technology (Caltech) have provided the first-ever glimpse of the structure of a key protein-gp120-found on the surface of a specific subgroup of the human immunodeficiency virus, HIV-1.

3 Apr 2010

Recent releases in Global Health

"Achieving the [Millennium Development Goal] MDG 4 target of reducing newborn and child mortality will require concerted efforts to scale up evidence-based interventions, especially community-based preventive and therapeutic strategies in primary care," according to a Lancet comment that reflects on the challenges associated with developing "the appropriate mix of strategies" to improve maternal health.

3 Apr 2010

T-cell cytolytic activity may be effective in clearing HBV infection

Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) poses a treatment challenge. In Western Europe and the United States, chronic HBV infection has been found in 6%󈝺% of HIV-positive patients and this co-infection is well known to be associated with increased liver-related morbidity and mortality. However, factors associated with HBV surface antigen (HbsAg) loss in HIV and HBV co-infected patients remain unclear.

31 Mar 2010

Researchers develop new compound to inhibit HIV transmission

A compound that can inhibit the transfer of HIV from one cell to another has been developed by researchers at the Institut de Biologie Structurale Jean-Pierre Ebel.

22 Mar 2010

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

CytoDyn, Inc. has begun full humanization of Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.

17 Mar 2010

Restoring immune function in HIV patients: Therapies targeting PD-1 and IL-10 molecules needed

New research conducted by the scientific director for VGTI Florida and his colleagues at the University of Montreal, in collaboration with scientists from the NIH and the McGill University Hospital center, may soon lead to an expansion of the drug arsenal used to fight HIV. The research sheds new light on how HIV gradually weakens the body’s immune system and highlights the need for new research into therapies that will target the chain of events that cause the progression of the disease.

17 Mar 2010

Booster shot appears to improve TB resistance in previously vaccinated adults

A booster shot appears to improve tuberculosis (TB) resistance in previously vaccinated adults, according to new research in South Africa.

17 Mar 2010

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced publication of data from a preclinical study in a clinically relevant animal model of sepsis showing that recombinant human Interleukin-7 (rhIL-7) treatment not only restores T cell trafficking and function, but also translates into improved survival.

16 Mar 2010

New study may lead to expansion of drug arsenal used to fight HIV

New findings from a Universit- de Montr-al and the Vaccine and Gene Therapy Institute of Florida (VGTI) study, in collaboration with scientists from the NIH and the McGill University Health Center, may soon lead to an expansion of the drug arsenal used to fight HIV.

9 Mar 2010

Study finds Pfizer's pneumonia, meningitis vaccine protects against recurrent pneumonia in HIV patients

Pfizer's Prevnar 7 vaccine, which protects against pneumonia and meningitis, has been shown to reduce the risk of recurrent pneumococcal infection in patients living with HIV in Malawi, according to a study published Thursday in the New England Journal of Medicine, Reuters reports.

5 Mar 2010

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Argos Therapeutics today announced the publication of a manuscript in the February edition of Clinical Immunology, detailing positive immune response, safety and manufacturing data for its AGS-004 immunotherapy for HIV. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden. The manuscript details a clinical study in which AGS-004 was evaluated in type-1 HIV-infected adults who were being treated with antiretroviral therapy (ART).

5 Mar 2010

Antiretroviral therapy reduces mortality rates in patients co-infected with HIV and TB

Initiating antiretroviral therapy (ART) during tuberculosis therapy significantly reduced mortality rates by 56 percent in a randomized clinical trial of 642 patients co-infected with HIV and tuberculosis. The study, which provides further impetus for the integration of TB and HIV services, lays to rest the controversy on whether co-infected patients should initiate ART during or after TB treatment.

26 Feb 2010

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

PointCare Technologies donates rapid PointCare NOW tests to Haitian clinics

PointCare Technologies, pioneer inventor of a portable diagnostic system that enables effective HIV/AIDS monitoring for millions of people in remote areas of developing countries, has donated 4,000 (a month's supply) of its rapid PointCare NOW tests to Haitian clinics to ensure the resumption of critical care to HIV/AIDS patients.

24 Feb 2010

News outlets examine use of ART, microbicide development presented at conference

News outlets continue to report on the science discussed at the Conference on Retroviruses and Opportunistic Infections (CROI), which ended Friday in San Francisco.

23 Feb 2010

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

VIRxSYS Corporation, a privately held company developing vaccines and RNA therapies for serious human diseases such as HIV and cardiovascular diseases, announced results from its prophylactic HIV vaccine (VRX1023) study in Rhesus Macaque monkeys during a presentation today at the 2010 Annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, CA.

19 Feb 2010

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

TenX Biopharma, Inc. announced today it has signed a licensing agreement to acquire exclusive worldwide rights to develop and commercialize zanolimumab (HuMax-CD4®) from Genmab A/S.

4 Feb 2010

New study may allow scientists to develop screening test for idiopathic pulmonary fibrosis

A simple blood test could predict which patients with the lung-scarring disease known as idiopathic pulmonary fibrosis (IPF) are soon to get far worse, an indicator that could one day influence their treatment, according to researchers at the University of Pittsburgh School of Medicine.

4 Feb 2010

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Tibotec Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a labeling update for PREZISTA® (darunavir) tablets to include 96-week data from the ARTEMIS and TITAN studies.

29 Jan 2010

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Researchers at The Scripps Research Institute have discovered a potential new way to stimulate the immune system to prevent or clear a viral infection. By blocking the action of a key protein in the mouse immune system, they were able to boost immune "memory" in those mice-work that may one day help doctors increase the effectiveness of human vaccines designed to prevent viral infections.

28 Jan 2010

CD4 News and Research

Scientists provide first-ever glimpse of HIV protein structure

Recent releases in Global Health

T-cell cytolytic activity may be effective in clearing HBV infection

Researchers develop new compound to inhibit HIV transmission

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

Restoring immune function in HIV patients: Therapies targeting PD-1 and IL-10 molecules needed

Booster shot appears to improve TB resistance in previously vaccinated adults

Cytheris study: rhIL-7 treatment restores T cell trafficking and improves survival in animal model of sepsis

New study may lead to expansion of drug arsenal used to fight HIV

Study finds Pfizer's pneumonia, meningitis vaccine protects against recurrent pneumonia in HIV patients

Argos Therapeutics' AGS-004 immunotherapy for HIV demonstrates clinical and commercial potential

Antiretroviral therapy reduces mortality rates in patients co-infected with HIV and TB

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

PointCare Technologies donates rapid PointCare NOW tests to Haitian clinics

News outlets examine use of ART, microbicide development presented at conference

VIRxSYS announces results from prophylactic HIV vaccine study at 2010 CROI conference

TenX Biopharma acquires exclusive global rights to zanolimumab from Genmab

New study may allow scientists to develop screening test for idiopathic pulmonary fibrosis

Labeling update for Tibotec Therapeutics' PREZISTA tablets approved

Blocking action of key protein boosts immune 'memory' to prevent or clear viral infection

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News